AUTHORS
Akshay Sharma Jr, MBBS, Alexis Leonard, MD2, Neha Das Gupta, PhD, CCRP3, Subodh Selukar4, Brandon Triplett, MD5, Clifford Takemoto, MD6, Doug Myers, MD7, Deepa Manwani I, MD8, Shengdar Tsai, PhD9, Frank Fazio, MS10, Timothy Lockey, PhD11, Catherine Willis, PhD12, Sheng Zhou, PhD13, Salem Akel, PhD14, Yan Zheng, MD, PhD15, Vijay Paladugu, MS, CCRP16, Rachel Hildebrand, BSN, CCRP17, Stephen Gottschalk, MD18, Jonathan Yen, PhD19, Mitchell Weiss, MD, PhD20
AFFILIATIONS
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
13 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
14 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
15 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
16 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
17 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
18 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
19 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
20 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
ABSTRACT
Introduction: The St. Jude Autologous Gene-Edited Stem Cells for Sickle Cell Disease-1 (SAGES1, NCT06506461) study is a single center phase 1 clinical trial to assess the safety of autologous CRISPR-Cas9 gene-edited CD34+ hematopoietic stem cells (HSCs) in individuals with sickle cell disease (SCD). CD34+ cells are edited at the γ-globin (HBG1/HBG2) promoters to disrupt binding of the transcriptional repressor BCL11A, thereby reactivating fetal hemoglobin (HbF) expression and reducing HbS polymerization in erythroid progeny. Currently, there are 2 FDA-approved gene therapies for SCD, and others are in development. These therapies employ diverse gene-editing and gene-addition strategies with distinct manufacturing processes. Although hematopoietic recovery and hemoglobin correction following these treatments have been well described, their effects on short- and long-term organ function and the durability of organ preservation remain insufficiently characterized, particularly in comparison to allogeneic hematopoietic cell transplantation (alloHCT). Consequently, the optimal curative approach(es) for SCD have yet to be defined. Our goal is to advance this knowledge with SAGES1 trial and accompanying long term follow up studies.
Study Design and Methods: The study population currently consists of patients with severe SCD (Hb SS, Hb Sβ0 and Hb Sβ+ genotype) aged 18-24.9 years. Severe SCD is defined as experiencing either (a) 2 or more SCD-related vaso-occlusive events (acute pain, acute chest syndrome, priapism, or splenic sequestration) per year in the 2-years before screening, OR (b) administration of regular red blood cell (RBC) transfusions for indications other than stroke prevention. Participants must have adequate organ function, negative infectious disease testing, and no HLA-matched sibling donor available. Patients with history of stroke, active malignancy or evidence of a pathogenic clonal variant are excluded from the study. After the initial safety and efficacy of the drug product have been established, we will expand the inclusion criteria to include pediatric patients. Twenty-five patients will be enrolled.
Study procedures include a) discontinuing hydroxyurea therapy and initiating RBC transfusions; b) CD34+ mobilization with motixafortide or plerixafor, followed by apheresis collection and immunomagnetic purification; c) electroporation of HSCs with Cas9-guide RNA ribonucleoprotein (RNP) targeting the BCL11A binding motif in the γ-globin promoters; d) conditioning of the participants with pharmacokinetically targeted busulfan; e) autologous infusion of the edited cells; and f) comprehensive short- and long-term follow-up. The primary objective of SAGES1 is to assess the safety of autologous infusion of CRISPR-Cas9-edited CD34+ HSCs in patients with severe SCD. The secondary objectives are to evaluate the efficacy of infusing autologous CRISPR-Cas9 genome-edited CD34+ HSCs into patients with severe SCD. In addition, we will pursue exploratory objectives focused on rheological, cerebrovascular, neurocognitive, cardiac, renal, pulmonary, and patient-reported outcomes, as well as health related quality of life. Participants will be followed for 3 years on SAGES1, and then an additional 12 years on an institutional long-term follow-up study (HEMLTFU, NCT06646640) as per FDA guidance.
Conclusion: We have developed and implemented SAGES1, a pilot clinical study, to assess the safety of a single infusion of autologous peripheral blood-derived CD34+ HSCs edited at the γ-globin promoters. We hypothesize that our strategy will be safe, lead to polyclonal multi-lineage engraftment, and lead to the induction of RBC HbF to levels that are sufficient to ameliorate the signs and symptoms of SCD. This is expected to improve rheologic parameters of RBCs and stabilization/ improvement of organ function. Importantly, SAGES1 will prospectively evaluate organ function alongside hematologic outcomes and directly compare participants with a contemporary cohort of alloHCT recipients enrolled on the same long-term follow-up study (HEMLTFU), providing a unique opportunity to assess the relative durability and clinical impact of these curative approaches. Information gained from SAGES1 will contribute to the advancement of curative therapies for individuals with SCD.
DISCLOSURES
Neha Das Gupta, PhD, CCRP: No relevant conflicts of interest to declare.